Platelet activating factor antagonist design: structure of methyl trans-5-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-2-oxo-4- furancarboxylate.
C14H16O6, Mr = 280.28, monoclinic, P2(1)/c, a = 6.070 (2), b = 9.526 (5), c = 22.418 (5) A, beta = 94.32 (2) degrees, V = 1293 A3, Z = 4, Dx = 1.44 g cm-3, lambda(Mo K alpha) = 0.71073 A, mu = 0.71 cm-1, F(000) = 592, T = 293 K, final R = 0.043 for 1400 observed [F0 greater than or equal to 5 sigma(F0)] reflections. The observed structure confirms a trans stereorelationship for the two substituents and an envelope conformation for the lactone ring. There is no crystallographically imposed symmetry. An analysis of the closest contacts in the cell lattice reveals two types of intermolecular interactions for this compound.
Peterson
J R
JR
Michael Faraday Laboratories, Department of Chemistry, Northern Illinois University, DeKalb 60115.
Smillie
T J
TJ
Rogers
R D
RD
D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003460:Crystallization; D005663:Furans / Q000138:chemical synthesis; D009682:Magnetic Resonance Spectroscopy; D015394:Molecular Structure; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D013055:Spectrophotometry, Infrared; D014961:X-Ray Diffraction
D005663:Furans; D010972:Platelet Activating Factor; C062513:methyl 5-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-2-oxo-4-furancarboxylate